July 31, 2018
1 min read

First patient dosed in Kala dry eye treatment trial

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The first patient has been dosed in a phase 3 trial of Kala Pharmaceuticals’ short-term dry eye treatment KPI-121 0.25%, the company announced in a press release.

The STRIDE 3 multicenter, randomized, double-masked, placebo-controlled, parallel arm trial will compare KPI-121 0.25% to placebo in approximately 900 patients with dry eye, with the primary endpoint being patient report of discomfort severity at day 15. Patients will be dosed four times a day for 14 days.

“If approved, KPI-121 0.25% could be the first FDA- approved product for the short-term treatment of dry eye disease,” Kala’s chief medical officer Kim Brazzell said. “The STRIDE 3 trial design reflects specific modifications to the inclusion/exclusion criteria of our previous trials to address key factors which we believe will improve the probability of success. We anticipate reporting topline results in the fourth quarter of 2019.”